Tubulin Isotypes: Emerging Roles in Defining Cancer Stem Cell Niche
Overview
Affiliations
Although the role of microtubule dynamics in cancer progression is well-established, the roles of tubulin isotypes, their cargos and their specific function in the induction and sustenance of cancer stem cells (CSCs) were poorly explored. But emerging reports urge to focus on the transport function of tubulin isotypes in defining orchestrated expression of functionally critical molecules in establishing a stem cell niche, which is the key for CSC regulation. In this review, we summarize the role of specific tubulin isotypes in the transport of functional molecules that regulate metabolic reprogramming, which leads to the induction of CSCs and immune evasion. Recently, the surface expression of GLUT1 and GRP78 as well as voltage-dependent anion channel (VDAC) permeability, regulated by specific isotypes of β-tubulins have been shown to impart CSC properties to cancer cells, by implementing a metabolic reprogramming. Moreover, βIVb tubulin is shown to be critical in modulating EphrinB1signaling to sustain CSCs in oral carcinoma. These tubulin-interacting molecules, Ephrins, GLUT1 and GRP78, are also important regulators of immune evasion, by evoking PD-L1 mediated T-cell suppression. Thus, the recent advances in the field implicate that tubulins play a role in the controlled transport of molecules involved in CSC niche. The indication of tubulin isotypes in the regulation of CSCs offers a strategy to specifically target those tubulin isotypes to eliminate CSCs, rather than the general inhibition of microtubules, which usually leads to therapy resistance.
Lopez-Collazo E, Hurtado-Navarro L Front Immunol. 2025; 16:1524781.
PMID: 39967663 PMC: 11832717. DOI: 10.3389/fimmu.2025.1524781.
Lin M, Mo Y, Li C, Liu Y, Feng X Med Oncol. 2025; 42(2):49.
PMID: 39827214 DOI: 10.1007/s12032-024-02586-0.
Targeting Histone Deacetylases 6 in Dual-Target Therapy of Cancer.
Beljkas M, Ilic A, Cebzan A, Radovic B, Djokovic N, Ruzic D Pharmaceutics. 2023; 15(11).
PMID: 38004560 PMC: 10674519. DOI: 10.3390/pharmaceutics15112581.
Ginsenosides on stem cells fate specification-a novel perspective.
Liu Y, Jiang L, Song W, Wang C, Yu S, Qiao J Front Cell Dev Biol. 2023; 11:1190266.
PMID: 37476154 PMC: 10354371. DOI: 10.3389/fcell.2023.1190266.
Ramesh Babu P J Genet Eng Biotechnol. 2023; 21(1):78.
PMID: 37466845 PMC: 10356719. DOI: 10.1186/s43141-023-00531-8.